Rheumatoid Arthritis -Exposure During Pregnancy
Conditions
Brief summary
Primary Objective: To evaluate the relative risk of major structural birth defects, specifically a pattern of anomalies, in sarilumab-exposed pregnancies compared to disease-matched unexposed pregnancies. Secondary Objective: To evaluate the risk for sarilumab-exposure relative to the group of healthy pregnant women, and the effect of exposure on other adverse pregnancy and infants outcomes.
Detailed description
Pregnant women enrolled in the study will participate for the duration of that pregnancy. Those who deliver at least one live born infant and the infants will participate for 1 year after delivery of that infant.
Interventions
Pharmaceutical form:injection Route of administration: subcutaneous
Sponsors
Regeneron Pharmaceuticals
Sanofi
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
FEMALE
Healthy volunteers
Yes
Inclusion criteria
* Cohort 1: Sarilumab-Exposed Cohort * Currently pregnant, exposed to Kevzara (sarilumab) for approved indication * Cohort 2: Disease-matched Comparison Cohort * Currently pregnant, diagnosed with Kevzara (sarilumab) approved indication * Cohort 3: Non-diseased Comparison Cohort * Currently pregnant, not diagnosed with a Kevzara (sarilumab) indication and unexposed to Kevzara
Exclusion criteria
First contact the Registry after prenatal diagnosis of any major structural defect or after pregnancy outcome is known (retrospective data). Enrolled in this cohort study with a previous pregnancy. Cohort 1: Sarilumab-Exposed Cohort * Exposed to Kevzara (sarilumab) for an indication other than a currently approved indication. * Exposure to another biologic during pregnancy or within 10 weeks prior to the first day of LMP. * Exposed to methotrexate, cyclophosphamide, chlorambucil, or mycophenolate mofetil in pregnancy (ie, at any time after the LMP), or leflunomide within two years prior to pregnancy unless a blood level for leflunomide below 0.02 mcg/mL has been documented prior to LMP before the pregnancy. * Cohort 2: Disease-matched Comparison Cohort * Exposure to any Kevzara (sarilumab) during pregnancy or within 10 weeks prior to the first day of the LMP. * Exposed to methotrexate, cyclophosphamide, chlorambucil, or mycophenolate mofetil in pregnancy (ie, at any time after the LMP), or leflunomide within two years prior to pregnancy unless a blood level for leflunomide below 0.02 mcg/mL has been documented prior to LMP before the pregnancy. * Cohort 3: Non-diseased Comparison Cohort * Diagnosed for any serious chronic disease that is thought to adversely impact pregnancy. * Exposed to a known human teratogen during pregnancy as confirmed by the OTIS Research Center The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Rate of major structural birth defect | Up to 1 year of age of the infant | A major structural birth defect is a defect that has either cosmetic or functional significance to the child (eg, a cleft lip) and is identified up to one year of age by the mother, the health care provider/medical record, or identified in the dysmorphological examination. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Pregnancy Outcomes: Stillbirth | After 20 weeks of gestation but prior to delivery | Stillbirth is defined as a non-deliberate fetal death that occurs at or after 20 weeks of gestation but prior to delivery. |
| Pregnancy Outcomes: Premature delivery | Live birth prior to 37 weeks gestation | Premature delivery is defined as live birth prior to 37 weeks' gestation as counted from LMP (Last Menstrual period). |
| Infant Outcomes: pattern of minor structural birth defects | Up to 1 year of age of the infant | A specific pattern of 3 or more structural defects in live born infants with dysmorphological physical examination. |
| Infant Outcomes: Small for gestational age | At birth | Proportion of infants less than or equal to the 10th percentile for sex and gestational age on weight, length, or head circumference. |
| Pregnancy Outcomes: Spontaneous abortion | Date of conception to 20 weeks gestation | Spontaneous abortion is defined as non-deliberate embryonic or fetal death that occurs \< 20.0 weeks' gestation post-LMP (Last Menstrual period). |
| Infant Outcomes: Serious or opportunistic infections | Up to 1 year of age of the infant | Proportion of infants who experienced serious or opportunistic infections up to 1 year of age. |
| Infant Outcomes: Hospitalizations | Up to 1 year of age of the infant | Proportion of infants who experienced hospitalizations in the first year of life excluding those that are linked to premature delivery or birth defects included as endpoints. |
| Infant Outcomes: Malignancies | Up to 1 year of age of the infant - | Proportion of infants who reported malignancies reported in an infant after birth and up to 1 year of age. |
| Infant Outcomes: Postnatal growth deficiency | Up to 1 year of age of the infant | Proportion of infants less than or equal to the 10th percentile for sex and age on weight, length, or head circumference at 1 year postnatal evaluation. |
Countries
Canada, United States
Outcome results
None listed